Novel non-nucleoside reverse transcriptase inhibitor (NNRTI)

Novel potent alkynyl bisubstrate inhibitor of nicotinamide N-methyltransferase (NNMT)

Iminosugar, binding to the active site of lysosomal beta-glucosidase and stabilizing the proper folding for the catalytic form, acting as a chemical chaperone that facilitate transport and maturation of acid beta-Glu

Novel selective histamine H3 antagonist

Novel inhibitor of autophagy, protecting cardiomyocytes against hypoxia/reoxygenation injury

Novel Potent and Highly Selective, Long-Acting, Peptide-Based Cholecystokinin 1 Receptor (CCK-1R) Agonist

Novel JAK2 inhibitor, displaying significant tumor growth inhibition in SET-​2 xenograft tumor model, with a mechanism of action confirmed in vivo by typical modulation of known biomarkers, and with a favorable pharmacokinetic and safety profile

Novel selective and orally bioavailable MPS1 inhibitor

Covalent and allosteric inhibitor of the ATPase VCP/p97, inducing cancer cell death

Novel Microtubule Modulator, Blocking Mitosis and Inducing Apoptosis in HeLa Cells by Binding to Tubulin

Novel Mdm2 inhibitor, acting as a negative regulator of p53, reducing viability in cell culture and suppressing tumor growth

Potent and state-dependent Nav1.7 antagonist

Novel Inhibitor of Nonsense-Mediated RNA Decay, Suppressing Nonsense p53 Mutations

Novel inhibitor of glioma-associated oncogene homologue 1 (Gli1) mediated transcription

Novel inhibitor of the Gli1 transcription, inducing apoptosis in cancer cells but not in non-cancerous cells

Novel Nm23-H1 activator, exerting cytotoxic effects on metastatic breast cancer cells by inducing mitochondrial dysfunction only under glucose starvation

Novel NLRP3 inhibitor, reducing caspase-1 activation, oligomerization of ASC, and therefore, IL-1β processing, showing a significant anti-inflammatory effect and reduced mechanical hyperalgesia at 3 and 10 mg/kg (i.p.) in an in vivo mouse of gout

Novel Enterovirus 71 Inhibitor, binding to the hydrophobic pocket in VP1 to block viral infection, exhibiting excellent antiviral activity (with an EC50 of 5.056 nM and a 100% protection rate for mice at a dose of 20 mg/kg) and low toxicity

Topoisomerase I inhibitor prodrug, slowly hydrolyzing and releasing irinotecan, increasing drug penetration into tumors and decreasing drug clearance

Neuroprotective, protecting neurons from death following cerebral anoxia (interruption of oxygen supply to the brain).

Novel pan-caspase inhibitor, potently reducing not only inflammasome-mediated interleukin-1β (IL-1β) secretion but also osteoclast differentiation in BMMs

Selective modulator of amyloid-beta peptide degradation, regulating Abeta levels

Antiviral agent against KFDV, AHFV, OHFV, as well as tick-borne encephalitis virus (TBEV) and mosquito-borne flaviviruses

Novel NIR NIR O2˙– probe, displays superior sensitivity to NIR O2˙– and having the capability to monitor trace amounts of intracellular NIR O2˙– in AKI in vivo

NIR emitting firefly luciferin analogue, displaying dose-independent improved NIR emission even at low concentrations where the native d-luciferin substrate does not emit

Novel precursor of bright-emission NIR-II fluorophores for in vivo tumor imaging and image-guided surgery

Novel highly selective and sensitive near-infrared fluorescent probe for imaging of hydrogen sulphide in living cells and mice

Novel self-immobilizing near-infrared (NIR) fluorogenic probe that can be activated by senescence-associated ß-galactosidase (SA-ß-Gal), the most widely used senescence marker

Novel potent PARP1 inhibitor

Novel potent tyrosine kinase inhibitor (TKI), targeting c-Met, VEGFR2 and Axl